Target Bacteria Discovery,
Microbiome Modulation,
Product Development

Target Bacteria Discovery,
Microbiome Modulation,
Product Development

BiomX Acquires RondinX to Boost Microbiome Discovery and Development Capabilities

...
LEARN MORE

BiomX Raises $24 Million in Series A Funding to Develop Microbiome Therapeutics

...
LEARN MORE

We discover and validate proprietary bacterial targets, and develop rationally designed phage therapies that seek and destroy harmful bacteria in microbiome-related diseases such as inflammatory bowel disease (IBD) and cancer.

Our technology was developed by world-leading scientists from top-tier institutions including MIT and the Weizmann Institute of Science.

LEARN ABOUT OUR LEADERSHIP

BiomX’s management and investors all have a long history of excellence that is propelling us to continued success.

LEARN ABOUT OUR BUSINESS LEADERSHIP

OUR 3-TIER MICROBIOME MODULATION PLATFORM

Our end-to-end platform enables identification of target bacteria that drive microbiome imbalance, and cutting-edge drug development to achieve precision microbiome modulation through targeted eradication or addition of specific bacteria.

Target Bacteria Discovery

Microbiome
Modulation

Product
Development

Real time discovery of novel
target bacteria through
mining the extremely complex
human microbiome

Treat disease by adding or
eradicating bacteria or phage
cocktails that are native
or engineered

Proprietary assays, processes,
and analyses to address pre-clinical
and clinical needs, leading to
commercialization

OUR INVESTORS